^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Esophageal Cancer

    Related cancers:
    1m
    Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer (clinicaltrials.gov)
    P2, N=2, Active, not recruiting, National Cancer Institute (NCI) | N=240 --> 2 | Trial completion date: Oct 2027 --> Jun 2027 | Trial primary completion date: Oct 2027 --> Jan 2026
    Enrollment change • Trial completion date • Trial primary completion date • MSI-H • dMMR
    |
    MSI (Microsatellite instability) • MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2)
    |
    MSI-H/dMMR
    |
    Tecentriq (atezolizumab) • docetaxel • capecitabine • oxaliplatin • leucovorin calcium • fluorouracil topical
    1m
    FREEDOM: Oral Paclitaxel Plus Fruquintinib Verus Investigator's Choice in Second-Line Advanced Gastric Cancer (clinicaltrials.gov)
    P=N/A, N=150, Recruiting, Harbin Medical University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    paclitaxel • docetaxel • albumin-bound paclitaxel • irinotecan • Fruzaqla (fruquintinib)
    1m
    Integrated Proteomics and Metabolomics Analysis Provides Insights into Metformin Down-regulating GLUL and SP1 to Inhibit Esophageal Squamous Cell Carcinoma Migration and Invasion. (PubMed, Recent Pat Anticancer Drug Discov)
    In summary, metformin may inhibit the migration and invasion of ESCC cells through downregulation of GLUL and SP1, which play important roles in the mechanism of metformin's anti-tumor effects. These findings provide new insights into the therapeutic potential of metformin in the treatment of ESCC.
    Journal • Metabolomic study
    |
    GLUL (Glutamate-Ammonia Ligase) • SP1 (Sp1 Transcription Factor)
    |
    metformin
    1m
    Neoadjuvant Short-Course Radiotherapy Plus Tislelizumab and Chemotherapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=50, Not yet recruiting, Tang-Du Hospital
    New P2 trial
    |
    carboplatin • Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel
    1m
    SWAT-BE: Seattle Biopsy Protocol Versus Wide-Area Transepithelial Sampling in Patients With Barrett's Esophagus Undergoing Surveillance (clinicaltrials.gov)
    P=N/A, N=2298, Recruiting, University of Colorado, Denver | Trial completion date: Mar 2026 --> Jun 2026 | Trial primary completion date: Mar 2026 --> Jun 2026
    Trial completion date • Trial primary completion date
    1m
    Retlirafusp Alfa Injection Plus Chemotherapy Versus Investigator's Choice of Anti-PD-1 Antibody Plus Chemotherapy as First-line Treatment for Advanced Gastric Cancer With Liver Metastases (clinicaltrials.gov)
    P3, N=332, Not yet recruiting, Peking University
    New P3 trial
    |
    Tyvyt (sintilimab) • Tevimbra (tislelizumab-jsgr) • capecitabine • oxaliplatin • retlirafusp alfa (SHR-1701)
    1m
    Evaluation of the Preliminary Efficacy and Safety of DR30206 in Combination With Standard Therapy in Patients With Gastrointestinal Cancer (clinicaltrials.gov)
    P1/2, N=186, Recruiting, Zhejiang Doer Biologics Co., Ltd. | Trial completion date: Jun 2026 --> Jun 2027 | Trial primary completion date: Apr 2026 --> Apr 2027
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative • HER-2 expression
    |
    5-fluorouracil • capecitabine • oxaliplatin • irinotecan • leucovorin calcium
    1m
    CH CARE: Clonal Hematopoiesis Chemotherapy and Radiation Effects Study (clinicaltrials.gov)
    P=N/A, N=5000, Recruiting, Dana-Farber Cancer Institute
    New trial
    1m
    Carboxy terminal of ECRG4 is a potential initiator for amyloid pathology in Alzheimer's disease through interacting with APP intracellular domain. (PubMed, J Alzheimers Dis)
    Furthermore, intracerebral injection of synthetic ECRG4(133-148) into AD model mice significantly augmented APP/Aβ deposition. Notably, the co-localization of ECRG4(133-148)-containing peptides with AICD-containing peptides increased with AD severity in human hippocampal tissue.ConclusionsOur findings establish that the carboxy-terminal fragment of ECRG4 acts as a potential initiator of amyloid pathology in AD through its interaction with AICD.
    Journal
    |
    APP (Amyloid Beta Precursor Protein)
    1m
    The application of continuous enteral nutrition during sequential chemoradiotherapy and immunotherapy in patients with esophageal cancer: a retrospective study. (PubMed, Support Care Cancer)
    Proactive continuous nutritional management improves patients' nutritional status and immune-related laboratory parameters during sequential sandwich therapy.
    Retrospective data • Journal
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
    1m
    POSIT: Neoadjuvant PD-1 Inhibitor Plus SOX Chemotherapy With or Without Short-Course Radiotherapy for Locally Advanced Upper Gastric or GEJ Adenocarcinoma (clinicaltrials.gov)
    P=N/A, N=146, Not yet recruiting, Tongji Hospital
    New trial • Tumor mutational burden
    |
    PD-L1 (Programmed death ligand 1)
    |
    Hetronifly (serplulimab)
    1m
    An amplification-free dual-readout biosensor integrating colorimetry and single-particle counting for ultrasensitive miRNA detection in esophageal cancer. (PubMed, Biosens Bioelectron)
    In a cohort of 60 clinical plasma samples (20 EC, 20 benign lesions, 20 healthy controls), the R2C digital readout showed an EC-associated elevation of plasma miR-320b relative to benign lesions and healthy controls, with trends consistent with reverse transcription quantitative PCR (RT-qPCR) on the same extracts. This work provides a practical route to amplification-free digital miRNA quantification using countable plasmonic labels and is readily extended to other circulating targets.
    Journal
    |
    MIR320A (MicroRNA 320a) • MIR320B (MicroRNA 320b)